Epirubicin HCl (56390-09-1) is an antitumor agent1. Inhibits topoisomerase II2. Induces DNA damage by a number of different mechanisms including intercalation, free radical-mediated oxidation, crosslinking, interference with DNA unwinding, strand separation and helicase activity3. Epirubicin HCl induces myocardial disfunction as a side effect to chemotherapy4.
1) Cersosimo et al. (1986), Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue; J. Clin. Oncol., 4 425
2) Spadari et al. (1986), DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs; Anticancer Res., 6 935
3) Minotti et al. (2004), Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity; Pharmacol. Rev., 56 185
4) Mercuro et al. (2007), Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers; Oncologist, 12 1124